Founders: Tom Miller (CEO), Fred Manby
Launched: 2020
Headquarters: San Diego, California
Funding: $350 million
Valuation: N/A
Key Technologies: Artificial intelligence
Industry: Biotech
Previous appearances on Disruptor 50 list: 1 (No. 26 in 2025)
If 2023 and 2024 were Iambic's coming out party, 2025 and 2026 have been all about proof of performance.
Late last year, the San Diego-based biotech company presented data that showed one of the drugs developed by its AI-driven drug discovery platform — a molecule called IAM1363 — showed promise treating multiple types of tumors.
What's more impressive is that Iambic was able to move the treatment from its discovery phase to its clinical trial initiation in just two years — shaving years off what can be one of the most time-consuming aspects of new drug development.
Iambic co-founder and CEO Tom Miller said in a statement at the time that this milestone validated his company's AI-first approach to drug discovery, adding, "With this foundation, we are advancing a robust pipeline of development candidates for both Iambic and our partners, redefining what's possible in drug discovery and development."
Investors and industry took notice. In November, Iambic announced it raised over $100 million in an oversubscribed fundraising round that included Sequoia, Regeneron and the Qatar Investment Authority. Then in February, Japanese pharmaceutical company Takeda signed a multiyear deal to access Iambic's drug discovery platforms for up to $1.7 billion.
That money will come in handy as Iambic looks to reinvest in its product pipeline beyond the cancer arena. The company lists five programs in some stage of development, including candidates for gastrointestinal and neurological conditions.
Execution will remain key for Iambic. In order to maintain momentum, the company will need to continue to produce clinical wins that help it distinguish itself from a growing list of competitors in the space.
Sign up for our weekly, original newsletter that goes beyond the annual Disruptor 50 list, offering a closer look at the most promising venture-backed companies.
